Clinical Studies and Trials
This trial will evaluate the effects of EryDex in patients with A-T.
The Platform is a patient-driven effort through which data about people with A-T are shared with researchers.
This study seeks to establish the natural history of pulmonary function decline in the A-T population.
This trial in the Netherlands looked at the effects of nicotinamide ribose as a potential treatment for people with A-T.
Participants with A-T demonstrated lower brain activity or metabolism in the cerebellum as compared to control participants.
At the dose tested, Baclofen did not have a significant effect on tremor, eye movement or balance deficits.
This open label study was performed to assess the safety and tolerability of the EryDex System in people with A-T.
These trials studied whether a low dose betamethasone would reduce neurological symptoms associated with A-T.
This trial was performed to see if amantadine sulphate improves ataxia or other movement disorders associated with A-T.
Among the 204 identified CSF proteins, 13 showed significant changes in A-T patients versus control samples.